Wire-Interwoven Nitinol Stent Outcome in the Superficial Femoral and Proximal Popliteal Arteries: Twelve-Month Results of the SUPERB Trial.
Garcia, Lawrence MD; Jaff, Michael R. DO; Metzger, Christopher MD; Sedillo, Gino MD; Pershad, Ashish MD; Zidar, Frank MD; Patlola, Raghotham MD; Wilkins, Robert G. MD; Espinoza, Andrey MD; Iskander, Ayman MD; Khammar, George S. MD; Khatib, Yazan MD; Beasley, Robert MD; Makam, Satyaprakash MD; Kovach, Richard MD; Kamat, Suraj MD; Leon, Luis R. Jr MD; Eaves, William Britton MD; Popma, Jeffrey J. MD; Mauri, Laura MD, MSc; Donohoe, Dennis MD; Base, Carol C. RN, MS; Rosenfield, Kenneth MD, MHCDS; for the SUPERB Trial Investigators *
Circulation: Cardiovascular Interventions.
8(5), May 2015.
(Format: HTML, PDF)
Background-: Stent-based therapy in the superficial femoral and popliteal arteries in patients with peripheral artery disease is compromised by restenosis and risk of stent fracture or distortion. A novel self-expanding nitinol stent was developed that incorporates an interwoven-wire design (Supera stent, IDEV Technologies, Inc, Webster, TX) to confer greater radial strength, flexibility, and fracture resistance.
Methods and Results-: This prospective, multicenter, investigational device exemption, single-arm trial enrolled 264 patients with symptomatic peripheral artery disease undergoing percutaneous treatment of de novo or restenotic lesions of the superficial femoral or proximal popliteal (femoropopliteal) artery. Freedom from death, target lesion revascularization, or any amputation of the index limb at 30 days ( 7 days) postprocedure was achieved in 99.2% (258/260) of patients (P<0.001). Primary patency at 12 months (360 /-30 days) was achieved in 78.9% (180/228) of the population (P<0.001). Primary patency by Kaplan-Meier analysis at 12 months (360 days) was 86.3%. No stent fracture was observed by independent core laboratory analysis in the 243 stents (228 patients) evaluated at 12 months. Clinical assessment at 12 months demonstrated improvement by at least 1 Rutherford-Becker category in 88.7% of patients.
Conclusions-: The SUPERB Trial, an investigational device exemption study using an interwoven nitinol wire stent in the femoropopliteal artery, achieved the efficacy and safety performance goals predesignated by the Food and Drug Administration. On the basis of the high primary patency rate, absence of stent fracture, and significant improvements in functional and quality-of-life measures, the Supera stent provides safe and effective treatment of femoropopliteal lesions in symptomatic patients with peripheral artery disease.
Clinical Trial Registration-: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00933270.
(C) 2015 American Heart Association, Inc.